Oncology EGFR-mutant lung cancer: Cracking the drug resistance code Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
